Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance to Market Genetic Tests Based on IP from U of Rochester and Mayo Clinic

NEW YORK, April 6 (GenomeWeb News) - Genaissance Pharmaceuticals said today that it has signed agreements with the University of Rochester and the Mayo Clinic for access to clinical research samples, associated data, and intellectual property around certain disease-associated mutations that it will use in developing genetic tests for cardiac disease.

Genaissance said it expects to launch the first such test, for cardiac ion channel mutations, in May. The test will include mutations responsible for Familial Long QT and Brugada Syndromes, and will be conducted in the company's CLIA-licensed laboratory in New Haven, Conn. 

"It is our intention to build a pharmacogenomic franchise around the genetics of cardiac ion channel mutations," said Richard Judson, senior vice president and CSO of Genaissance, in a statement.

As part of the agreements, Michael Ackerman, associate professor at the Mayo Clinic College of Medicine and director of the Long QT Syndrome Clinic, and Arthur Moss, professor of medicine at the University of Rochester, will serve on Genaissance's advisory board.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.